Grafico Azioni Astrazeneca (LSE:AZN)
1 Anno : Da Feb 2019 a Feb 2020
By Ian Walker
AstraZeneca PLC (AZN.LN) said Tuesday that Farxiga met the primary endpoint in a Phase 3 trial for the treatment of patients with heart failure.
The pharmaceutical giant said Farxiga significantly reduced the risk of cardiovascular death or worsening of heart failure when added to standard of care.
Write to Ian Walker at email@example.com
(END) Dow Jones Newswires
August 20, 2019 02:25 ET (06:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.